Related Experiment Videos
Hydralazine-induced hepatitis in pregnancy
M Hod1, S Friedman, A Schoenfeld
1Department of Obstetrics and Gynecology, Beilinson Medical Center, Petah Tiqva, Israel.
International Journal of Fertility
|November 1, 1986
Summary
Hydralazine, a common treatment for pregnancy-induced hypertension, may contribute to HELLP syndrome development. This syndrome involves hemolysis, thrombocytopenia, and elevated liver enzymes, potentially linked to hydralazine
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Hepatology
Background:
- Pregnancy-induced hypertension (PIH) affects liver function and can lead to HELLP syndrome in 5-10% of preeclamptic patients.
- Hydralazine (1-hydrazinophthalazine) is frequently used to manage PIH.
- The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) is a serious complication of pregnancy.
Purpose of the Study:
- To investigate the potential role of hydralazine in the development of HELLP syndrome in patients with pregnancy-induced hypertension.
- To examine hydralazine's impact on hepatocellular damage in this patient population.
Main Methods:
- Retrospective analysis of 38 patients treated with hydralazine for pregnancy-induced hypertension in 1983.
- Monitoring for clinical and laboratory evidence of HELLP syndrome during hydralazine treatment.
Main Results:
- Five out of 38 patients (approximately 13%) developed HELLP syndrome during hydralazine therapy.
- Findings suggest a possible association between hydralazine administration and the occurrence of hepatocellular damage.
Conclusions:
- Hydralazine, while a common treatment for PIH, may be implicated in the pathogenesis of HELLP syndrome.
- Further research is warranted to clarify the risks and benefits of hydralazine in patients susceptible to HELLP syndrome.